851069-96-0

Basic information

• Product Name: (6-[4-(TRIFLUOROMETHOXY)PHENYL]PYRIDIN-3-YL)METHANOL
• Synonyms: (6-[4-(TRIFLUOROMETHOXY)PHENYL]PYRIDIN-3-YL)METHANOL;[6-[4-(TrifluoroMethoxy)phenyl]-3-pyridyl]Methanol;6-[4-(trifluoromethoxy)phenyl]-3-Pyridinemethanol;2-(4-(Trifluoromethoxy)phenyl)pyridine-5-methanol
• CAS NO: 851069-96-0
• Molecular Formula: C₁₃H₁₀F₃NO₂
• Molecular Weight: 269.22
• Mol File: 851069-96-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (6-[4-(TRIFLUOROMETHOXY)PHENYL]PYRIDIN-3-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (6-[4-(TRIFLUOROMETHOXY)PHENYL]PYRIDIN-3-YL)METHANOL(851069-96-0)
• EPA Substance Registry System: (6-[4-(TRIFLUOROMETHOXY)PHENYL]PYRIDIN-3-YL)METHANOL(851069-96-0)

Safety Data

• Hazardous Substances Data: 851069-96-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(6-[4-(TRIFLUOROMETHOXY)PHENYL]PYRIDIN-3-YL)METHANOL is used as a building block for the synthesis of more complex organic molecules. Its unique chemical properties, particularly the trifluoromethoxy group, contribute to the formation of diverse molecular structures with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (6-[4-(TRIFLUOROMETHOXY)PHENYL]PYRIDIN-3-YL)METHANOL is used as a starting material for drug design and development. Its structural features make it a promising candidate for the creation of new pharmaceutical compounds with potential therapeutic applications.

Upstream product

• 149806-06-4 6-bromonicotinaldehyde 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 
• 851069-97-1 6-(4-(trifluoromethoxy)phenyl)nicotinaldehyde 

Relevant articles and documents

Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility

Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.

Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents

This invention relates to compounds of the formula wherein one of R6, R7 and R8 is and X, Y1 to Y4, R1 to R14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.

Phenyl derivatives, their manufacture and use as pharmaceutical agents

This invention relates to compounds of the formula wherein one of R5, R6 and R7 is and X1, X2, Y1 to Y4, R1 to R13 and m and n are defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.